Reaction
Ophthalmic Herpes Zoster reporting signals
As of the last recalculation, Ophthalmic Herpes Zoster appears in 1,764 FAERS reports alongside 33 co-occurring drug terms. The strongest observed disproportionality signal is BARICITINIB (PRR 23.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Baricitinib | 19 | 23.5 | 23.5 |
| Prednisolone Acetate | 13 | 14.9 | 14.9 |
| Valacyclovir Hydrochloride | 75 | 13.1 | 13.1 |
| Sirolimus | 14 | 12.4 | 12.4 |
| Valacyclovir | 41 | 11.9 | 11.9 |
| Upadacitinib | 74 | 11.1 | 11.1 |
| Cladribine | 8 | 9.9 | 9.9 |
| Ocrelizumab | 48 | 9.4 | 9.4 |
| Infliximab-Dyyb | 22 | 9.0 | 9.0 |
| Desoximetasone | 13 | 8.1 | 8.1 |
| Timolol | 8 | 7.8 | 7.8 |
| Brimonidine Tartrate | 11 | 7.3 | 7.3 |
| Belimumab | 19 | 7.1 | 7.2 |
| Abiraterone | 8 | 7.0 | 7.0 |
| Fingolimod Hcl | 47 | 6.6 | 6.6 |
| Efavirenz | 6 | 6.4 | 6.4 |
| Diroximel Fumarate | 6 | 6.0 | 6.0 |
| Tofacitinib Citrate | 6 | 5.4 | 5.4 |
| Tofacitinib | 78 | 5.2 | 5.2 |
| Natalizumab | 74 | 5.0 | 5.0 |
| Dimethyl Fumarate | 50 | 4.9 | 4.9 |
| Polatuzumab Vedotin | 4 | 4.8 | 4.8 |
| Botulinum Toxin Type A | 5 | 4.8 | 4.8 |
| Vedolizumab | 33 | 4.6 | 4.6 |
| Lifitegrast | 6 | 4.3 | 4.3 |
| Aflibercept | 10 | 3.8 | 3.8 |
| Encorafenib | 3 | 3.6 | 3.6 |
| Ranibizumab | 8 | 3.6 | 3.6 |
| Teriflunomide | 13 | 3.4 | 3.4 |
| Cenegermin-Bkbj | 3 | 2.9 | 2.9 |
| Abiraterone Acetate | 10 | 2.9 | 2.9 |
| Guselkumab | 8 | 2.6 | 2.6 |
| Ixekizumab | 7 | 2.2 | 2.2 |